Treatment of melancholia with tranylcypromine.
Nine of 12 outpatients meeting DSM-III criteria for melancholia responded to treatment with the monoamine oxidase inhibitor (MAOI) tranylcypromine. Responders were less depressed before treatment and after treatment than were nonresponders. MAOIs appear useful in treating endogenous depressions.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D001714:Bipolar Disorder / Q000188:drug therapy / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D014191:Tranylcypromine / Q000627:therapeutic use*
D014191:Tranylcypromine